바카라 용어 secures Japanese patent for CAR-T therapy candidate VCB-1203

[by Jin, Yu Jeong] Vaxcellbio announced on January 19 that it has successfully secured patent registration in Japan for its chimeric antigen receptor T-cell (CAR-T) treatment candidate, ‘VCB-1203 (development code),’ designed to target the immune checkpoint protein ‘PD-L1.’

The company stated that the Japanese patent registration constitutes international validation of the core technology underlying its anti-PD-L1 CAR-T treatment candidate, particularly with respect to its superior non-clinical efficacy, safety, and stability. 바카라 용어 further noted that, together with its existing domestic patent portfolio, this registration is expected to serve as an opportunity to actively secure intellectual property (IP) rights across key global markets.

VCB-1203 is a CAR-T therapy candidate under development for the treatment of various solid tumors, including refractory and recurrent gastric, colorectal, pancreatic, and ovarian cancers. Relative to existing CAR-Ts derived from ‘avelumab’ and ‘atezolizumab,’ VCB-1203 preserves comparable binding affinity to cancer cells while demonstrating a more rapid dissociation rate following target engagement. In non-clinical studies, the candidate exhibited robust therapeutic efficacy, safety, and stability, achieving sustained long-term tumor cell cytotoxicity while minimizing off-target toxicity to normal cells.

바카라 용어 is currently developing a next-generation, dual-target CAR-T therapy for solid tumors that simultaneously targets EphA2 in addition to PD-L1. The company reported that this multi-target CAR-T program has received international recognition, having been selected for support under a Korea Drug Development Fund (KDDF) ​​project in June 2024, followed by its participation in a research initiative by the National Cancer Center in September 2025.

바카라 용어 is actively pursuing patent protection for its CAR-T and natural killer (NK) cell-based therapies in jurisdictions including Japan and Australia and is gradually establishing a global intellectual property portfolio spanning Asia and Oceania. Of the company's total 17 patents, four are registered as international patents. 바카라 용어 expects that this growing international IP portfolio will serve as strategic leverage in future technology transfer agreements and co-development negotiations with global pharmaceutical and biotechnology partners.

"The registration of this patent in Japan demonstrated that our solid tumor CAR-T platform, including VCB-1203, has been recognized for its competitiveness not only in the Korean market but also on a global scale," said Lee Je-jung, CEO of Vaxcellbio. "Building on the acquisition of overseas patents, including those secured in Japan, we intend to actively advance global clinical development programs and pursue technology transfer opportunities for our solid tumor CAR-T therapies," he added.